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Abstract Deletion of 13q14.3 and a candidate gene
KCNRG (potassium channel regulating gene) is the most
frequent chromosomal abnormality in B-cell chronic
lymphocytic leukemia and is a common finding in
multiple myeloma (MM). KCNRG protein may interfere
with the normal assembly of the K+ channel proteins
causing the suppression of Kv currents. We aimed to
examine possible role of KCNRG haploinsufficiency in
chronic lymphocytic leukemia (CLL) and MM cells. We
performed detailed genomic analysis of the KCNRG
locus; studied effects of the stable overexpression of
KCNRG isoforms in RPMI-8226, HL-60, and LnCaP
cells; and evaluated relative expression of its transcripts
in various human lymphomas. Three MM cell lines and 35
CLL PBL samples were screened for KCNRG mutations.
KCNRG exerts growth suppressive and pro-apoptotic
effects in HL-60, LnCaP, and RPMI-8226 cells. Direct
sequencing of KCNRG exons revealed point mutation delT
in RPMI-8226 cell line. Levels of major isoform of
KCNRG mRNA are lower in DLBL lymphomas compared
to normal PBL samples, while levels of its minor mRNA
are decreased across the broad range of the lymphoma
types. The haploinsufficiency of KCNRG might be
relevant to the progression of CLL and MM at least in a
subset of patients.
Keywords Tumorsuppressorcandidate.Potassium
channels.13q14.Chroniclymphocyticleukemia.Multiple
myeloma.KCNRG
1 Introduction
B-cell chronic lymphocytic leukemia (B-CLL) represents
22–30% of all leukemia cases, thus being the most
commonly diagnosed form of leukemia in the Western
world [1, 2]. This disease is usually seen amongst the
elderly [2]. On a cellular level, the disease progresses due to
the prolonged survival of B-CLL cells arrested in the G0
stage of the cell cycle [3, 4] This prolonged survival causes
the accumulation of quiescent small CD5(+) B lymphocytes
which are frozen at an early step of maturation and have
decreased susceptibility to apoptotic cell death. Latter
features of CLL are commonly attributed to the imbalance
in various cytoplasmic pro-survival and pro-death path-
ways, including the BCR-signaling pathway [3, 5, 6]. In
addition, a small number of “atypical” Ki-67 expressing
lymphocytes are frequently observed in the bone marrow of
CLL patients [7]. Proliferation rates of these lymphocytes
vary among patients and even among subpopulations of
cells within the leukemic clones of individual patients [8].
A newly evolving point of view at CLL stresses that blood
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DOI 10.1007/s13277-009-0005-0lymphocyte count in individual patients represents a
dynamic interplay between ongoing birth and death within
the clones rather than a linear, monotonous accumulation of
inert leukemic cells [8].
The most frequent chromosomal abnormalities in B-CLL
are deletions on 13q14 and 17p13, trisomy 12, and
rearrangements of 14q32. Being the most common abnor-
mality in CLL [9, 10], deletions at 13q14.3 are associated
with the longest survival. Rearrangements and/or deletions
in the region of 13q14.3 are found in many other types of
hematopoietic malignancies, including 38% of mantle cell
lymphomas [11] and approximately 54% of multiple
myelomas (MM) as detected by fluorescence in situ
hybridization [12, 13]. In the majority of these non-CLL
cases, 13q14 deletions are associated with a poor chemo-
therapy response profile. In addition, deletions of 13q14.3
are common in prostate cancer [14] and in some other solid
tumors.
Attempts to delineate the minimal common deleted
region (CDR) in CLL and MM cells lead to highlighting
a region adjacent to marker D13S319 [9, 13, 15, 16]. This
region encompasses an area containing the previously
described tumor suppressor gene candidates DLEU1,
DLEU2, RFP2, and KCNRG as well as microRNAs miR-
15a and miR-16-1 [9, 16–19]. DLEU1 and DLEU2
candidates are represented by a number of non-coding
RNAs [15, 20]. Direct sequencing and single-strand
conformation polymorphism (SSCP) screening of the
RFP2 gene encoding E3 ubiquitin ligase revealed no
mutations [13, 19, 21]. Recently, a haploinsufficiency
mechanismhasbeenproposedasamajormodeofinactivation
of 13q14 tumor suppressor gene(s). According to this
mechanism,deletionofa singleactivecopyof13q14.3results
insignificantdownregulationofthecandidategene(s)andloss
of function [22].
Candidate tumor suppressor gene KCNRG (potassium
channel regulating gene) is located within the 3′ end of the
largest transcript of RFP2 [23] and encodes a protein with
a high homology to the tetramerization domain of voltage-
gated K+ channels (Kv channels). This protein may
interfere with the normal assembly of the K+ channel
proteins by binding to their tetramerization domain,
thereby, causing the suppression of Kv currents. This
hypothesis was consequently confirmed using the patch-
clamp technique in the human androgen-sensitive prostate
cell line LnCaP [23]. As Kv channels are involved in the
proliferation of both LnCaP cells [24] and normal
lymphocytes [25], while being upregulated in neoplastic
hematopoietic cells [26], we hypothesized that KCNRG
may exert a tumor suppressor effect relevant to CLL and
MM.
To investigate the possibility of KCNRG involvement in
the pathogenesis of these diseases, we performed detailed
genomic analysis of the KCNRG locus; studied effects of
the stable overexpression of KCNRG isoforms in the model
cell lines RPMI-8226, HL-60, and LnCaP; and evaluated
relative expression of its transcripts in various human
lymphomas.
2 Materials and methods
2.1 Mutation screening
This study was performed using peripheral blood samples
obtained from 35 B-CLL patients and ten donors with
informed consent and Institutional Review Board approval.
Peripheral blood mononuclear cells were isolated by a
standard procedure using Ficoll-Hypaque gradient centrifu-
gation and used for total DNA preparation and purification
by phenol/chlorophorm protocol [27]. Median absolute
number of lymphocytes was 57,000/ul (range 24,000–
187,000); therefore, in all cases, fraction of mononuclear
cells contained mostly B-CLL cells. Primer sequences for
amplifying the coding region of the KCNRG gene were
chosen according to Cho et al. All cases were screened for the
presence of an aberrant band in the tumor DNA by SSCP
analysis of each exon and compared with the normal DNA.
Highly polymorphic repeat (A)33(TA)8(CA)8TATGTA(CA)2
TACA (TA)4CA(TA)3 has been amplified with primers 5′-
GTA AAC ATA GCA AGA CCC AGT-3′ and 5′-CAT TTC
CTG CTC TTG CCA TGT-3′; average amplicon length was
158 bp. KCNRG exons along with adjacent areas were
directly amplified on the DNA templates of MM cell lines
NCI-H929, RPMI-8226, and U266 and subjected to auto-
mated sequencing.
2.2 Cloning of human KCNRG isoforms
All basic molecular biology and microbiology procedures
(plasmid isolation, cloning, Escherichia coli transformation,
and cultivation) were performed according to standard
protocols [27]. Human KCNRG-L (mRNA isoform B) and
KCNRG-S (mRNA isoform A) were cloned into the
pcDNA3.1/myc-His vector (Invitrogen, San Diego, CA,
USA). The cloning of KCNRG-L was performed by
OriGene (Rockville, MD, USA) using archived full-length
cDNA clone corresponding to mRNA isoform NM_173605.
For KCNRG-S isoform, a polymerase chain reaction (PCR)
product encompassing its full-length open reading frame was
amplified from human brain mRNA, cloned into pGemT-
Easy vector (Promega), then transferred to pcDNA3.1/myc-
His. The restriction enzymes BamH1 and XhoI were used
for the cloning of both KCNRG isoforms. Bidirectional
sequencing of the plasmids and PCR clones with vector or
gene-specific primers were performed by fluorescence-
34 Tumor Biol (2010) 31:33–45tagged chain termination (Big Dye Terminator, Applied
Biosystems), according to the manufacturer's protocol,
followed by fractionation on an ABI 310 automated DNA
sequencer (Applied Biosystems). Two primer pairs were
designed to confirm authenticity of the inserts: pair V1
capable of amplifying both isoforms of KCNRG with
product sizes of 107 basepairs and 129 basepairs, and pair
V2, specifically amplifying KCNRG-S specific product of
129 basepairs. Primer sequences were as follows: V1 5′-
TTTTCCCTCCTCAGATGACC-3′ and 5′-TCCAGT
TTGGTTATCAGTAGTGC-3′,V 25 ′-CCTGGTTTT
CCAGTGTG GTT-3′,a n d5 ′-GCTGAGGCAGGAGAA
TCACT-3′.
2.3 LnCaP, HL-60, and RPMI-8226 cells stably expressing
KCNRG-L and KCNRG-S
Cell lines LNCaP, HL-60, and RPMI-8226 were obtained
from American Type Culture Collection (Manassas, VA,
USA) and maintained in RPMI-1640 containing 2 mM
glutamine, 10 mM HEPES, and 10% fetal calf serum
(Invitrogen, San Diego, CA, USA). The cDNA-containing
or empty control plasmids were transfected into LNCaP,
HL-60, and RPMI-8226 cells with Transfectol (Gene
Choice, Frederick, MD, USA). Stably transfected cells
were selected using 500 ug/ml of Geneticin (Sigma) and
were subsequently maintained in 75 cm
2 flasks with
antibiotic. Expression of KCNRG isoforms was confirmed
by real-time PCR as described below.
2.4 Cell proliferation and apoptosis assays
For cell proliferation and apoptosis assays, cells were
seeded in 96-well black plates with clear bottoms (Thermo
Electron) at a density of 2×10
4 per well (proliferation
assay) or 3.5×10
4 per well (apoptosis assay) in 100 ul of
RPMI-1640 media with 10% fetal calf serum. For the
proliferation assays, 32 wells were seeded with stably
transfected cells, vector control cells, and wild-type parental
cell line along with eight no-cell background controls. In
experiments with transiently transfected cells, an extra set
of 16 wells with mock-transfected cells were added.
Apoptosis assays were performed in 96 well plates in sets
of 8-well replicates for each cell type. Cell proliferation
rates were quantified by enzyme-linked immunosorbent
assay (ELISA) Chemiluminescent BrDU (Roche). As
recommended by the manufacturer, the optimal incubation
times were determined experimentally, 48 h for RPMI-8662
and HL-60 and 72 h for LnCaP. Apoptosis rates were
determined using the CaspaseGLO 3/7 luminescent Assay
(Promega, Madison, WI, USA) that measures caspase-3
and -7 activities after 2 h of incubation. Chemolumines-
cence was quantified using microplate fluorometer
Fluoroskan Ascent (Thermo Scientific). Both apoptosis
and cell proliferation assays were performed in eight
replicates.
2.5 FACS analysis
Cell cycle distribution was analyzed by flow cytometry as
described earlier [28]. Briefly, 0.5×10
6 to 1.5×10
6 cells
were transfered to 15 ml conical tubes, washed twice with
cold phosphate buffer solution (PBS), centrifuged at 1,000 g
for 5 min, and resuspended in 1 mL of PI staining solution
(PBS+50 ug/ml PI+100 ug/ml RNAse A). Cells were
incubated at 4°C in the dark for 20 min and were analyze
on FACSCalibur (Becton Dickinson) within 15–30 min.
Quantification of cell death was performed by staining with
Annexin V/7-AAD kit (BD Pharmingen, San Jose, CA,
USA). Washed and centrifuged pellets were resuspended in
0.1 ml of 1× binding buffer, then 10 µl of annexin Vand 5 µl
of 7-AAD were added to each sample. Cells were gently
pipetted and incubated at room temperature for 15 min in the
dark. Following incubation, 0.9 ml of 1× binding buffer was
added to the cells. The samples were analyzed within 1 h of
staining. Controls stained with Annexin V only and 7-AAD
only were performed for calibration purposes. During the
experiments, cells were kept on ice and away from light
sources.
2.6 Cell imaging
Cells were rinsed in PBS briefly to remove media
components and fixed in freshly prepared 4% parafor-
maldehyde/PBS solution for 15 min at room temperature.
Cells were permeabilized by adding 0.1% Triton-X100 in
PBS for 1 min. A PBS-diluted solution of Rhodamine
phalloidin (1:100 in PBS), 5 uL of 300 nM DAPI, and
4u Lo fd i l u t e dD I O C1 8s o l u t i o nw e r ea d d e dt ot h e
permeabilized cells. The mixture was incubated for 15 min
at room temperature. Following staining, the cells were rinsed
in PBS three times and mounted onto slides with cover slips;
slides were kept in the dark and in the freezer until imaging.
Images were taken on a Nikon Eclipse 90i microscope
equipped with a Nikon C1 confocal scan head and laser lines
at 406, 488, and 568 nm.
2.7 Invasion and migration assays
To evaluate migratory and invasive properties of the cells
overexpressing KCNRG, fluorimetric CytoSelect 96well
Cell Migration and Invasion, CytoSelect 24-wells Anoikis,
and CytoSelect Leukocyte Transmigration Assays (Cell
Biolabs, Inc, San Diego, CA, USA) were used according to
the manufacturer's protocols. Invasion and migration assays
were performed in three replicates.
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For reverse-phase protein microarrays methodology, the
protein lysates were loaded into 384-well plates and each
serially diluted in lysis buffer to a five-point dilution
curve (neat, 1/2, 1/4, 1/8, and 1/16). Each dilution series
was printed in duplicate onto nitrocellulose-coated glass
slides (Whatman, Inc., Sanford, ME, USA) with a 2470
Arrayer (Aushon BioSystems, Burlington, MA, USA).
Slides were desiccated and stored at −20°C. Before
antibody staining, the lysate arrays were treated with
mild Reblot antibody stripping solution (Chemicon,
Temecula, CA, USA) for 15 min at room temperature,
washed twice for 5 min in phosphate-buffered saline, and
then incubated for at least 5 hi nb l o c k i n gs o l u t i o n[ 1g
I-block (Tropix, Bedford, MA, USA), 0.1% Tween-20 in
500 ml phosphate-buffered saline] at room temperature
with constant rocking. Blocked arrays were stained with
antibodies on an automated slide stainer (Dako Cytoma-
tion, Carpinteria, CA, USA) using the Catalyzed Signal
Amplification System kit according to the manufacturer's
recommendation (CSA; Dako Cytomation). Briefly, en-
dogenous biotin was blocked for 10 min with the biotin
blocking kit (Dako Cytomation), followed by application
of protein block for 5 min; primary antibodies were diluted
in antibody diluent and incubated on slides for 30 min, and
biotinylated secondary antibodies were incubated for
15 min. Signal amplification involved incubation with a
streptavidin–biotin–peroxidase complex provided in the
CSA kit for 15 min and amplification reagent (biotinyl-
tyramide/hydrogen peroxide, streptavidin-peroxidase) for
15 min each. Development was completed by using
diaminobenzadine/hydrogen peroxide as the chromogen/
substrate. Slides were allow e dt oa i rd r ya f t e rd e v e l o p -
ment. We specifically chose 38 primary antibodies to
analyze broad signaling pathways thought to be involved
in the proliferation and apoptosis-related signaling. Sec-
ondary antibodies and dilutions included biotinylated goat
anti-rabbit IgG (H_L) 1:5,000 (Vector Laboratories,
Burlingame, CA, USA) and biotinylated rabbit anti-
mouse IgG 1:10 (Dako Cytomation). Stained slides were
scanned individually on a UMAX PowerLook III scanner
(UMAX, Dallas, TX, USA) at 600 dpi and saved as TIF files
in Photoshop 6.0 (Adobe, San Jose, CA, USA). The TIF
images for antibody stained slides and Sypro-stained slide
images were analyzed with MicroVigene image analysis
software, version 2.200 (Vigenetech, North Billerica, MA,
USA), and Microsoft Excel 2000 software. Images were
imported into Microvigene, which performed spot finding,
local background subtraction, replicate averaging, and total
protein normalization, producing a single value for each
sample at each endpoint (see Supplementary Table 1 for
antibody details).
2.9 Real-time PCR profiling of KCNRG in human
lymphoma samples and cell lines
To assess KCNRG gene expression in human lymphoma
samples, TissueScan Tissue qPCR Arrays Panels were
purchased from OriGene Technologies, Inc (Rockville,
MD, USA). The pre-normalized cDNAs per each panel
were composed of six normal, ten follicular lymphomas, 11
diffuse large B-cell lymphomas, three small lymphocytic
lymphomas, six Hodgkin lymphomas, eight marginal zone
B-cell lymphomas, two mantle cell lymphomas, and three
T-cell lymphomas. Reactions were performed in a 96-well
format in 30 uL reactions in the BioRad iCycler iQ Real-
Time Detection System (BioRad Laboratories, Hercules,
CA, USA). For KCNRG isoforms, three independent PCR
experiments on individual pre-normalized Tissue Scan
plates from the same manufacturer's batch were performed.
Primers used for real-time PCR profiling of KCNRG
isoforms were KCNRG-SL primers 5′-TTTTCCCT
CCTCAGATGACC-3′ and 5′-TCCAGTTTGGTTATCAG
TAGTGC-3′; KCNRG-S primers 5′-CCTGGTTTTCC
AGTGTGGTT-3′ and 5′-GCTGAGGCAGGAGAATC
ACT-3′. Additional normalization was performed in tripli-
cate using Beta Actin control primers provided by the
manufacturer. The presence of a single specific PCR
product was verified by melting curve analysis and
confirmed on agarose gels.
For an assessment of endogenous and overexpressed
levels of KCNRG transcripts, total RNA preparates were
isolated by Qiagen RNeasy Mini Kit (Valencia, CA, USA)
from wild-type cell lines LNCaP, HL-60, and RPMI-8226
(ATCC, Manassas, VA, USA) as well as from their
derivatives stably expressing KCNRG-S, KCNRG-L, and
pcDNA3.1 backbone control. Reverse transcription reac-
tions were performed using 2 μg of total RNA and
SuperScript® Reverse Transcriptase (RT; Invitrogen, San
Diego, CA, USA). Reactions were heated at 70°C for 5 min
in a total volume of 12.5 μl in the presence of 100 ng of
random hexamers (Invitrogen) and cooled at room temper-
ature for 1 min. After a mini-centrifuge spin, 4 μl of 5× first
strand buffer (Invitrogen), 2 μl of 0.1 M DTT, and 0.5 μlo f
25 mM dNTP mix (Fisher Scientific) were added to the
reaction. The mixture was then incubated at 42°C for 1 h.
The resulting cDNA was stored frozen (−80°C) until
assayed by real-time PCR. PCR reactions were performed
in a 96-well format in the BioRad iCycler iQ real-time
Detection System (BioRad Laboratories, Hercules, CA,
USA). The real-time PCR mixtures contained 1 μlo ft h e
RT sample, 400 nM each of forward and reverse primers,
and 1× iQ SYBR Green Super Mix and were carried out in
a total volume of 15 μl. Amplification of 18S RNA in
parallel with the genes of interest was performed as an
internal normalization standard with previously described
36 Tumor Biol (2010) 31:33–45primers 18S-F 5′-AGGAATTCCCAGTAAGTGCG-3′ and
18S-R 5′-GCCTCACTAAACCATCCAA-3′ [19, 29]. For
each gene of interest and 18S RNA, three to four
independent PCR experiments from the same RT sample
were performed.
2.10 Computer programs and statistical analysis
Comparative analysis in silico and an analysis of the
structure of the KCNRG gene were performed using
genomic, mRNA and EST databases (http://www.ncbi.
nlm.nih.gov and http://genome.ucsc.edu). The KCNRG
promoter was predicted by Core Promoter (http://www.
cshl.edu/OTT/html/corepromoter.html) and NNPP (http://
www.fruitfly.org/seq_tools/ promoter.html) services. Search
for known single nucleotide polymorphisms (SNPs) was
performed in National Center for Biotechnology Informa-
tion dbSNP build 129. A search for TF binding sites and
promoter elements was performed using MatInspector
algorithm and Matrix Family Library Version 7.1 (June
2008 release, http://www.genomatix.de/). MAR/SAR ele-
ments were predicted by SMARTest (www.genomatix.de).
Multiple alignments of the protein sequences were per-
formed using ClustalW v.1.83. A phylogenetic tree of
prealigned T1 domains of KCNRG-like proteins was
reconstructed by the neighbor-joining method and visual-
ized by the same software. Group comparisons were
performed by non-parametric Mann–Whitney hypothesis
tests. Unless otherwise noted, P values <0.05 were
considered significant.
2.10.1 Supplementary materials
Supplementary Figures 1 and 2 as well as Supplementary
Table 1 could be downloaded at http://mason.gmu.edu/
∼abaranov/pages/completed%20project%20pages/Compl-
KCNRG.html.
3 Results
3.1 mRNA and protein isoforms of KCNRG gene
Candidate tumor suppressor gene KCNRG resides within
the 3′ end of the largest transcript of RFP2 gene described
earlier [19, 30]. Major mRNAs of KCNRG are transcribed
independently of RFP2, starting at the promoter located
within 3′-untranslated region RFP2 (Fig. 1). This sequence
is adjacent to in silico predicted promoter located in the
position approximately 100 nt upstream of the putative 5′
end of the KCNRG transcripts according to an alignment of
the KCNRG ESTs to genome (Core Promoter score 1.000,
NNPP score 0.97). Additionally, RT-PCR experiments
support existence of a hybrid mRNA isoform that includes
1 2
3
3
3
1 2 3
RFP2 mRNA isoforms:
1 2 3
1 2 3
1 2 3
KCNRG mRNA isoforms:
1 2 3
1 3
Hybrid RFP2/KCNRG mRNA isoform:
1 2 3
14154 bp
2747 bp 1286 bp
Encodes protein 
KCNRG-S
Encodes protein 
KCNRG-L
NM_199464
NM_173605
KCNRG ex
KCNRG ex
KCNRG ex
KCNRG ex
RFP2 locus
KCNRG locus
RFP2 ex         long form
RFP2 ex          long form
PK PR
Fig. 1 Genomic organization of
RFP2/KCNRG gene locus.
Schemes represent the structure
of the mRNA isoforms of the
human RFP2 and KCNRG
genes and the hybrid mRNA
isoform. Open reading frame of
RFP2 is represented by white
arrow. Open reading frames of
KCNRG are represented by
black arrows. Hybrid mRNA
RFP2/KCNRG is not translated.
Promoter of RFP2 marked as
PR, promoter of KCNRG
marked as PK
Tumor Biol (2010) 31:33–45 37exons from both RFP2 and KCNRG (Fig. 1). This isoform
originates from the quadruplex containing promoter of
RFP2, possibly due to its unusual properties [31]. In all
examined species of mammals with the exception of
primates, KCNRG and RFP2 genes are encoded by separate
loci (Supplementary Figure 1). Prediction of MAR/SAR
elements that exhibit enhanced affinities for nuclear matrix
binding does not reveal any of these in mouse locus and
only one such element in the intron of RFP2 in rat genome,
while KCNRG/RFP2 locus in human genome contains five
of these elements, possibly indicating substantial differ-
ences in the principles of the regulation of these genes in
humans and rodents.
Human KCNRG encodes two protein isoforms KCNRG-
L (272 aa) and KCNRG-S (229aa) differing in their C-ends
and possessing common N-end of 184 aa. A T1 tetrame-
rization domain covers amino acid positions 7 to 98.
KCNRG loci of non-human mammals encode only one
protein isoform corresponding to human KCNRG-L. In
chimps, KCNRG-L differs from its human orthologue by
one amino acid substitution (Pro → Leu) in the position
158. Comparison of human and rat KCNRG orthologues
revealed 85.4% identity in 268 residue overlap, while
comparison with mouse orthologue was characterized by
73.2% identity in 264 residue overlap. Murine KCNRG
locus encodes two protein isoforms, 264 and 191 residues
in length, both of which are variants of human KCNRG-L
isoform.
Interestingly, human KCNRG-S and KCNRG-L iso-
forms are different by their C-tails, as these proteins share
only first 191 amino acids. N-end difference is due to out-
of-frame insertion of the alternatively spliced exon 2 that is
present only in the human genome and is derived from
AluSp SINE repeat. Human mRNA isoforms encoding two
KCNRG proteins are co-expressed in the same set of tissues
(not shown). Levels of Alu-containing KCNRG-S mRNA
isoform are substantially lower than that of KCNRG-L
mRNA.
3.2 KCNRG is a member of the KCTD protein family
Human KCNRG is a member of the KCTD protein family
that encodes predicted proteins with an N-terminal domain
homologous to the T1 domain in voltage-gated potassium
channels. KCTD family proteins belong to a larger group of
non-channel T1/BTB proteins. KCTD family members are
similar to Pfam K_tetra consensus (PF02214) rather than
that of BTB/POZ [32]. Our analysis (Fig. 2; Supplementary
Figure 2) revealed two previously unclassified KCNRG-
like proteins that belongs to KCTD family, TNFAIP1
(tumor necrosis factor-alpha-induced protein 1) and
SHKPB1 (SH3KBP1 binding protein 1), while pointing
that the protein C6orf69 previously described as KCTD20
represents an outgroup and should be excluded from the T1
family in a sensu stricto. Most of the KCTD proteins are
relatively short (on average, 355 aminoacids). Their T1
1 2 3
1 2 3
Human RFP2 and KCNRG:
5' 3'
1 2 3
1 2
Rat Trim13 and Kcnrg:
5' 3'
1 2 1 2
Mouse Trim13 and Kcnrg:
5' 3' 1 2
102 4636 1414
1515
650 3547 1182
22
217
99
7043 1243
2162
572 3522 235
754 3233 114 10828 6533
3320 818 2753
98 1295 709
1 2
818 4146
709
Fig. 2 An alignment of
KCNRG with other proteins
of KCTD family. Degree of
shading indicates different
degree of conservation for a
given amino acid position:
invariant positions are darkest,
other conserved positions are
shaded lighter, and non-
conserved positions are not
shaded. Total length of T1
domain, its position, and full
length of the proteins are
summarized in the table adjacent
to the aligned protein sequences.
Truncated versions of T1
domain are marked by star
38 Tumor Biol (2010) 31:33–45domains are located close to the N-end of the protein and
are not accompanied by any other Pfam domains. KCTD19
protein is the only KCTD member that contains two tandem
T1 domains, first of which is truncated. T1 domains in three
out of 25 KCTD proteins, namely, KCTD18, KCTD11, and
KCTD9L, are truncated. KCNRG is a typical member of
the KCTD family, with solitary T1 domain unaccompanied
by any other recognizable protein structure.
3.3 Variations in KCNRG locus
Mutations within open reading frame of KCNRG and
adjacent parts of its introns were screened in 35 CLL
patients by conventional PCR-SSCP. No aberrant bands
were seen. Direct sequencing of KCNRG exons revealed
point mutation delT in the +30 position of the 5′ non-
coding area of the gene in RPMI-8226 cell line (position
indicated according to mRNA Ac. Num. NM_199464). The
search for known human SNPs was negative for any match
in this nucleotide position. Interestingly, an analysis of
matches to transcription factor binding matrices with
MatInspector software revealed the core promoter initiator
element (INR) that overlaps with this mutated position.
Deletion of T decreases matrix similarity of the match from
0.945 to 0.941, and therefore, might negatively influence
expression of KCNRG in RPMI-8226 cells.
A low complexity repeat (A)33(TA)8(CA)8TATGTA
(CA)2TACA(TA)4CA(TA)3 located at the position 1006
relative to the major start of KCNRG mRNAs and within 3′
untranslated area of RFP2 was amplified by PCR with
subsequent band resolution in polyacrilamide gel in 21
DNA sample of CLL patients and 50 DNA samples of
normal donors. Unusually high level of the polymorphism
has been observed, as the profiling of a total of 142
chromosomes revealed 12 alleles of this repeat. Heterozy-
gous state of this repeat was seen in 52/71 (73%) samples
tested indicating high informativeness of this polymorphic
DNA marker.
3.4 Expression of KCNRG inhibits proliferation
and enhances apoptosis in cultured tumor cells
Open reading frames corresponding to both protein iso-
forms of KCNRG were stably transfected in LNCaP, HL-
60, and RPMI-8226 cells and studied in various functional
assays. The cells transfected with pcDNA3.1 vector alone
were used as a control. As quantified by chemiluminescent
BrdU cell proliferation ELISA assay, growth of all three
cell lines was significantly inhibited by an overexpression
of KCNRG-L isoform (RPMI-8226: decrease of 37%,
P<0.001; HL-60: decrease of 26%, P<0.0025; LNCaP:
decrease of 38%, P<0.009). KCNRG-S isoform exerted
less prominent growth suppressive effect in these cells
(RPMI-8226: decrease of 27%; HL-60: decrease of 12%;
LNCaP: decrease of 24%). In the case of KCNRG-S
isoform, the differences between observed values were
ab c
de f
Fig. 3 Expression of KCNRG inhibits proliferation and enhances
apoptosis. Axis Y reflects chemoluminescence readings (ChemU) in
respective assays. a–c Results BrdU enzyme-linked immunosorbent
assay to quantify proliferation in HL-60 (a), RPMI-8226 (b), and
LnCaP (c) cells. d–f Results of the caspase assays to quantify
apoptosis in HL-60 (d), RPMI-8226 (e), and LnCaP (f) cells
Tumor Biol (2010) 31:33–45 39significant only for KCNRG-S overexpression in LNCaP
(P<0.05) and RPMI-8226 (P<0.02; Fig. 3a–c).
Cell survival was analyzed by measurement of the
activities of caspases 3 and 7 (Fig. 3d–f). We revealed an
increase in the apoptotic events in the cells that were stably
transfected with any KCNRG isoform, but in KCNRG-L
cells, these changes were more profound (KCNRG-L/
RPMI-8226: increase of 180%, P<0.0008; KCNRG-
L/HL-60: increase of 216%, P<0.0008; KCNRG-L/
LNCaP: increase of 46%, P<0.0002; KCNRG-S/RPMI-
8226: increase of 94%, P<0.0008; KCNRG-S/HL-60:
increase of 25%, NS; KCNRG-S/LNCaP: increase of
41%, P<0.0002).
Observations described above were confirmed by FACS
analysis of the cell lines overexpressing KCNRG isoforms
and the vector control (Figs. 4 and 6). Interestingly, the
suppression of the proliferation of the suspension cell lines
HL-60 and RPMI-8226 has been accompanied by the
dramatic changes in the size and the shape of the cells. An
increase of KCNRG-L expression in HL-60 cell line resulted
in the formation of two cell populations, normal-like
population mainly residing in G1 phase (Fig. 4f, g,q u a d r a n t s
1 and 3) and larger, abnormal cells residing in G2 (Fig. 6f, g,
quadrants2and4).Similarly,anoverexpressionof KCNRG-L
in RPMI-8226 also produced a population of abnormal cells
(not shown). Cell imaging studies indicated a change of
Q1 Count: 264
Q2 Count: 160
Q3 Count: 9456
Q4 Count: 120
Q1 Count: 175
Q2 Count: 820
Q3 Count: 6843
Q4 Count: 2162
HL-60: vector control HL-60: KCNRG-L HL-60: vector control HL-60: KCNRG-L
HL-60: vector control and HL-60: KCNRG-L
overlay
a
b
c
d
e
fg
Fig. 4 Propidium iodide FACS analysis of the cell cycle in the vector
control and KCNRG-L overexpressing HL-60 cells. a, b Scatter plot
and frequency histogram reflecting cell sizes and DNA content in HL-
60 cells transfected with empty vector (vector control). c, d Scatter
plot and frequency histogram reflecting cell sizes and DNA content in
HL-60 cells transfected with KCNRG-L overexpressing plasmid. e
Overlay of images (a) and (c). f, g Detailed frequency histograms
displaying DNA content of vector control HL-60 cells (f) and
KCNRG-L overexpressing HL-60 cells (g) located by their size in
each of four quadrants
40 Tumor Biol (2010) 31:33–45morphology in KCNRG overexpressing cells and generally
confirmed FACS findings (Figs. 5 and 6).
3.5 Expression of KCNRG does not influence invasion
of LNCaP cells but affects migration of the suspension cell
lines HL-60 and RPMI-8226
Migration of RPMI-8226 cells stably transfected KCNRG-S
and KCNRG-L as well as vector control has been studied
using 0.2–2.0×10
6 cells/ml and fetal bovine serum as
chemoattractant. Migration of KCNRG-L overexpressing
cells were not different from that of the control cells, while
migration abilities of KCNRG-S were significantly lower
(KCNRG-S, N=28, 3.46±0.408 vs. control, N=28, 2.75±
0.67, P<0.004). Analysis of the transmigration of the vector
control and KCNRG overexpressing HL-60 cells through the
monolayer of endothelial cell revealed that KCNRG-L
decreases ability of the cells to penetrate endothelium
(KCNRG-L, N=5, 17.19±0.26 vs. control, N=5, 18.41±
0.59, P<0.01), while overexpression of KCNRG-S leads to a
non-significant increase in the transmigratory abilities of this
cell line. Study of the adherent LNCaP cells revealed that
overexpression of the KCNRG isoforms does not influence
their ability to cross basement membrane (not shown). Study
of LNCaP anoikis showed that both KCNRG overexpressing
and vector control cells are dying upon detachment, thus
indicating no influence of KCNRG on the anoikis related
cell death (not shown).
3.6 Proteome changes associated with KCNRG
overexpression
To evaluate differences in intracellular molecular networks
associated with overexpression of KCNRG, we attempted
RPA profiling of the changes in the broad spectrum of the
cellular signaling events, with emphasis on the phosphor-
ylation and proteolytic events associated with proliferation
and apoptosis. In all three cell lines, an overexpression of
either isoform of KCNRG was associated with decreased
activation of mTOR by phosphorylation of serines 2481 and
A. B. C. D.
E. F. H. G.
HL-60 
Control 
HL-60
KCNRG-L
RPMI-8226
Control 
RPMI-8226
KCNRG-L 
I. J. K. L.
M. N. O. P.
Fig. 5 Images of HL-60 cells. a–d HL-60/control. e–h HL-60/
KCNRG-L. i–l RPMI-8226/control. m–p RPMI-8226/KCNRG-L.
Cells stained with lipohilic probe Dioc 18 (a, e, i, m), Nucleic acid
probe DAPI (b, f, j, n), and F-actin probe rhodamine phalloidin (c, g,
k, o). Overlay of the individual images (d, h, l, p). Original
magnification ×100
Tumor Biol (2010) 31:33–45 412448 and decreased phosphorylation of tyrosine 1175 in
VEGFR2. In RPMI-8226, overexpression of KCNRG iso-
forms lead to the coordinated increase of cleavage events in
caspases 3, 6, 7, and 9 and the caspase target protein PARP. In
LNCaP cells, overexpression of KCNRG resulted in para-
doxicalprofoundincreaseinERKsignalingasrevealedbythe
phosphorylation of Threonine 202 and Tyrosine 204.
3.7 Real-time PCR profiling of KCNRG mRNAs in human
lymphoma samples
Relative levels of KCNRG isoforms were quantified in
human lymphoma samples arrayed on TissueScan qPCR
panels (Fig. 7). As expression of the major isoform of
KCNRG mRNA encoding KCNRG-L was 300 times higher
than that of the minor mRNA isoform (KCNRG-S), mRNA
level estimatesobtained using primer pair KCNRG-SL can be
approximated to the expression of KCNRG-L encoding
isoform. We revealed significant downregulation of
KCNRG-L mRNA (P<0.05) in the most advanced lympho-
mas of the stage IV (N=4) as compared to normal
PBL samples (N=6). When the same set of samples were
stratified according to the type of lymphoma, a significant
downregulation of KCNRG-L was registered only in DLBL
(N=11) as compared to normal PBL samples (P<0.002).
Interestingly, only one case of DLBL was classified as stage
IV disease, while six of these cases were stage I, and four
were staged as IE or IIE. A trend towards downregulation of
abc HL-60: vector control HL-60: KCNRG-L HL-60: KCNRG-S
d
e
HL-60: vector control
HL-60: KCNRG-L 
overlay
HL-60: vector control
HL-60: KCNRG-S 
overlay
f
Q1
(necrosis)
Q2
(late apoptosis)
Q3
(no cell death)
Q4
(early apoptosis)
215
44
2272
657
-2575
-853
88
152
L
S
KCNRG 
isoforms
Fig. 6 Quantification ofcelldeathinHL-60/control, HL-60/KCNRG-L,
and HL-60/KCNRG-S by staining with Annexin V/7-AAD. a–c
Scatter plots and frequency histograms reflecting cell sizes and
staining with Annexin V/7-AAD in HL-60 cells vector control (a),
HL-60 cells transfected with KCNRG-L overexpressing plasmid (b),
and HL-60 cells transfected with KCNRG-L overexpressing plasmid
(c). d Overlay of images (a)a n d( b). e Overlay of images (a)a n d( c).
f Bar graph reflecting relative changes in the number of cells stained
with Annexin V/7-AAD after transfection with KCNRG isoforms.
Q1 reflects necrosis, Q2 reflects late apoptosis, Q3 reflects healthy
cell population not affected by apoptosis or necrosis, and Q4 reflects
early apoptosis
42 Tumor Biol (2010) 31:33–45the KCNRG-S encoding mRNA was seen in all lymphoma
types profiled, with statistically significant differences seen
in FL (P<0.002), DLBL (P<0.02), and T-cell lymphoma
(P<0.03) groups. Stage-wise, significant decrease in the
level of mRNA for KCNRG-S was seen in stage I (P<0.008)
and IIE (P<0.04) groups.
4 Discussion
Previous studies of the tumor suppressor effects conveyed
by presence of an intact chromosome 13 region q14.3
revealed a number of potential candidate genes whose
expression is lost in a substantial percentage of CLL cases
[9, 16–19, 33]. Despite significant effort undertaken by
multiple laboratories, a screening of the mutations in the
studied candidate genes in primary tumor cells has not yet
been successful. These findings prompted some investiga-
tors to propose that a major mode of inactivation of 13q14
tumor suppressor gene(s) is by the deletion of one copy of
the gene causing decrease in the production of gene' mRNA
and partial loss of its function [21, 22]. This mechanism
gene inactivation is known as haploinsufficiency. Impor-
tantly, haploinsufficiency implies that the deleted region
ab
cd
Fig. 7 Real-time polymerase chain reaction (PCR) profiling of
KCNRG mRNAs in human lymphoma samples. N Normal PBL, FL
follicular lymphoma, DLBL diffuse large B-cell lymphoma, SLL small
lymphocytic lymphoma, HL Hodgkin lymphoma, MZBL marginal
zone B-cell lymphoma, MCL mantle cell lymphoma, TL T-cell
lymphoma. a, b Reverse transcription (RT)-PCR profiling using
primer pair KCNRG-SL that amplifies both isoforms of KCNRG
mRNA. c, d RT-PCR profiling using primer pair KCNRG-S that
amplifies only mRNA isoform KCNRG-S. Statistically significant
changes denoted by star symbol. Expression levels of KCNRG-L/S
and KCNRG-S isoforms are reflected at Y axis in artificial expression
units (AU) after normalization to β-actin mRNA levels
Tumor Biol (2010) 31:33–45 43may contain more than one gene participating in the
suppression of the tumor development, a feature that is
especially relevant in light of particular importance of the
conservative miRNA-16 locus for the development of CLL
like disorder in New Zealand mice [33].
Candidate tumor suppressor gene KCNRG (potassium
channel regulating gene) is located very close to the 10-kb
region previously described as CDR in CLL and within
larger region deleted in the majority of CLL cases with
13q14.3 aberrations [9, 23]. Functional analysis of KCNRG
[23] pointed at the possibility that it might exert a tumor
suppressor effect relevant to CLL and MM. Additionally, a
missense mutation at codon 92 within the T1 domain of
KCNRG was found in one hepatocellular tumor [34].
Analysis of the Hep3B hepatoma cells revealed that in this
cell line, KCNRG has growth suppressive activity [34]. In
this paper, we demonstrated that KCNRG possesses similar
activity when overexpressed in RPMI-8226 and HL-60 cells.
Moreover, overexpression of KCNRG stimulates apoptosis
in these cells and leads to dramatic changes in their size and
shape. A substantial proportion of both RPMI-8226 and
HL-60 cells overexpressing isoform KCNRG-L was arrested
in G2 phase, possibly indicative of G2/M checkpoint
activation. Additionally, migration of KCNRG overexpress-
ing cells has also significantly decreased. Finally, KCNRG
overexpression increased a propensity of the cells to undergo
apoptosis after the stress, in particular, affecting its ability to
recover after the storage in frozen state (not shown).
One way to confirm the relevance of these characteristics
of human KCNRG to the suppression of CLL and MM in
vivo is to find its point mutations in the primary tumor
cells. Our and others' attempts to do so were unsuccessful.
However, a number of circumstantial evidences points at
KCNRG as an important player in hematological malignan-
cies. First, real-time PCR profiling of KCNRG mRNAs
revealed that levels of the major KCNRG isoform in DLBL
lymphomas are lower compared to normal PBL samples,
while levels of its minor mRNA are decreased across the
broad range of the lymphoma types. Levels of the KCNRG
mRNA were also decreased in the lymphomas of the stage
IV. Second, MM cell line RPMI-8226 contains delT
mutation in the core promoter initiator element that might
influence levels of KCNRG expression in this model line.
Third, proteomics endpoint analysis by RPA indicated an
involvement of KCNRG in the suppression of mTOR and
VEGFR pathways as well as in caspase activation in a
broad sense. In light of these observations, an identification
of the particular mode of KCNRG inactivation in the tumor
samples becomes a priority. Despite a number of studies
that delineated 13q14 deletions in CLL and MM and
quantified relative expression levels of some candidate
genes residing in this area, the critical insights related to the
role of 13q14 role in human malignancies are still to be
gained. Here, we described a novel, highly informative
polymorphic repeat, located at the position 1006 relative to
the major start of KCNRG mRNAs and within 3′ untrans-
lated area of RFP2. As the structure of this repeat allows its
relatively simple visualization in agarose gels after conven-
tional PCR, it might become a valuable marker for the
hemizygous deletion of KCNRG in primary tumor samples.
Interestingly, KCNRG belongs to rather large subfamily
of the poorly characterized human genes (Fig. 2). Some of
these genes functions in tumorigenesis: SH3KBP1 sup-
presses cathepsin B-mediated apoptosis [35]; hedgehog
antagonist REN (KCTD11) regulates proliferation and
apoptosis of developing granule cell progenitors and
suppresses medulloblastoma genesis [36]; and expression
of the KCTD12 (pfetin) serves as a negative prognostic
biomarkers for gastrointestinal stromal tumors [37]. As
cellular functions for the majority of the KCNRG-like
proteins have never been studied, it is important to
determine their relevance to the tumorigenesis and lym-
phomagenesis in humans.
In conclusion, we conducted a functional study of the
tumor suppressor gene candidate KCNRG and demonstrated
its growth suppressive and pro-apoptotic effects in the
cellular models relevant to CLL and MM. We conclude that
the effects of the loss of KCNRG might be relevant to the
progression of these hematological malignancies at least in
a subset of the patients with these disorders.
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